Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system, has scheduled its Q1 2025 financial results release and business update for May 9, 2025.
The company will host a conference call and webcast at 8:30 a.m. EDT to discuss financial results and provide updates on corporate and regulatory developments. The call will be accessible via toll-free numbers for domestic and Israeli callers, with international lines available. A replay will be available for two weeks through the company's investor relations website.
Protalix BioTherapeutics (NYSE American: PLX), una società biofarmaceutica specializzata in proteine terapeutiche ricombinanti tramite il proprio sistema proprietario di espressione in cellule vegetali ProCellEx®, ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale per il 9 maggio 2025.
La società terrà una conference call e una webcast alle 8:30 a.m. EDT per discutere i risultati finanziari e fornire aggiornamenti sugli sviluppi aziendali e regolatori. La chiamata sarà accessibile tramite numeri verdi per chiamanti nazionali e israeliani, con linee internazionali disponibili. Una registrazione sarà disponibile per due settimane sul sito web delle relazioni con gli investitori della società.
Protalix BioTherapeutics (NYSE American: PLX), una compañía biofarmacéutica especializada en proteínas terapéuticas recombinantes utilizando su sistema de expresión en células vegetales patentado ProCellEx®, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 y una actualización empresarial para el 9 de mayo de 2025.
La empresa realizará una llamada en conferencia y una transmisión web a las 8:30 a.m. EDT para discutir los resultados financieros y proporcionar actualizaciones sobre desarrollos corporativos y regulatorios. La llamada será accesible mediante números gratuitos para quienes llamen desde Estados Unidos e Israel, con líneas internacionales disponibles. Una repetición estará disponible durante dos semanas a través del sitio web de relaciones con inversionistas de la compañía.
Protalix BioTherapeutics (NYSE American: PLX)는 자체 개발한 ProCellEx® 식물 세포 기반 발현 시스템을 이용한 재조합 치료 단백질에 특화된 생명공학 회사로, 2025년 1분기 재무 실적 발표 및 사업 현황 업데이트를 2025년 5월 9일에 예정하고 있습니다.
회사는 재무 실적을 논의하고 기업 및 규제 관련 최신 정보를 제공하기 위해 동부 표준시 기준 오전 8시 30분에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 이 통화는 국내 및 이스라엘 발신자를 위한 무료 전화번호와 국제 전화 라인을 통해 접속할 수 있습니다. 녹음된 내용은 회사 투자자 관계 웹사이트를 통해 2주간 다시 들을 수 있습니다.
Protalix BioTherapeutics (NYSE American : PLX), une société biopharmaceutique spécialisée dans les protéines thérapeutiques recombinantes utilisant son système d'expression propriétaire à base de cellules végétales ProCellEx®, a programmé la publication de ses résultats financiers du premier trimestre 2025 et une mise à jour commerciale pour le 9 mai 2025.
L'entreprise organisera une conférence téléphonique et une webdiffusion à 8h30 EDT pour discuter des résultats financiers et fournir des mises à jour sur les développements corporatifs et réglementaires. L'appel sera accessible via des numéros gratuits pour les appelants nationaux et israéliens, avec des lignes internationales disponibles. Une rediffusion sera disponible pendant deux semaines sur le site web des relations investisseurs de la société.
Protalix BioTherapeutics (NYSE American: PLX), ein biopharmazeutisches Unternehmen, das sich auf rekombinante therapeutische Proteine unter Verwendung seines proprietären ProCellEx®-Pflanzenzell-Expressionssystems spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 und ein Unternehmensupdate für den 9. Mai 2025 angekündigt.
Das Unternehmen wird eine Telefonkonferenz und ein Webcast um 8:30 Uhr EDT abhalten, um die Finanzergebnisse zu besprechen und Updates zu unternehmensbezogenen und regulatorischen Entwicklungen zu geben. Der Anruf ist für Anrufer aus den USA und Israel über gebührenfreie Nummern zugänglich, internationale Leitungen sind ebenfalls verfügbar. Eine Aufzeichnung wird für zwei Wochen über die Investor-Relations-Website des Unternehmens abrufbar sein.
- None.
- None.
Company to host conference call and webcast at 8:30 a.m. EDT
CARMIEL,
Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.
Conference Call Details:
Date: Friday, May 9, 2025
Time: 8:30 a.m. Eastern Daylight Time (EDT)
Toll Free: 1-877-423-9813
International: 1-201-689-8573
Israeli Toll Free: 1-809-406-247
Conference ID: 13753682
Call me™: https://tinyurl.com/yey23rkc
The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
Webcast Details:
Company Link: https://ir.protalix.com/news-events/events
Webcast Link: https://tinyurl.com/3nn9jh5v
Conference ID: 13753682
Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-first-quarter-2025-financial-and-business-results-on-may-9-2025-302445855.html
SOURCE Protalix BioTherapeutics, Inc.
FAQ
When will Protalix BioTherapeutics (PLX) release its Q1 2025 earnings?
How can investors access Protalix BioTherapeutics' (PLX) Q1 2025 earnings call?
What is Protalix BioTherapeutics' (PLX) main technology platform?
How long will the replay of PLX's Q1 2025 earnings call be available?
